Pharmaceuticals

This channel includes news and new technology innovations for cardiovascular pharmaceutics. This includes antiplatelet agents, anticoagulation drugs, INR testing, NOAC, OAC, IV administered drugs such as Heprin, and dual antiplatelet therapy.

ACC/AHA Update Guidance for Preventing Heart Disease; Stroke
Feature | Cardiac Diagnostics | March 18, 2019
March 18, 2019 — The choices we make every day can have a lasting effect on our heart and vascular health. Adopting a...
Researchers Develop Reversible, Drug-Free Antiplatelet Therapy
News | Antiplatelet and Anticoagulation Therapies | February 19, 2019
February 19, 2019 — A new reversible, drug-free antiplatelet therapy could reduce the risk of blood clots and...
Two of the top news items from January included news atrial fibrillation guidelines that now recommend new anticoagulants (NOACs) over warfarin, and the FDA warning hospitals about the increased mortality found in one study involving pacitaxel-eluting stents and balloon devices for the peripheral arteries.

Two of the top news items from January included news atrial fibrillation guidelines that now recommend new anticoagulants (NOACs) over warfarin, and the FDA warning hospitals about the increased mortality found in one study involving pacitaxel-eluting stents and balloon devices for the peripheral arteries. 

Feature | February 01, 2019 | Dave Fornell, Editor
February 1, 2019 — Here is the list of the most popular content on the Diagnostic and Interventional Cardiology (DAIC)...
Research Sheds Light on Blood Pressure Drug Function
News | Hypertension | January 31, 2019
January 31, 2019 — Researchers have mapped the active-state structure of the angiotensin II type 1 receptor, the target...
Rivaroxaban is among four new oral anticoagulants (NOAC) now recommended by atrial fibrillation guidelines over the old standard of warfarin.

Rivaroxaban is among four new oral anticoagulants (NOAC) now recommended by atrial fibrillation guidelines over the old standard of warfarin.

 

Feature | Atrial Fibrillation | January 30, 2019
January 30, 2019 — Updated atrial fibrillation (AFib) treatment guidelines released this week now recommend new oral...
The startup company Genetesis introduced a new cardiac imaging modalityit calls magnetocardiography. The scanner creates images from the biomagnetic activity of the heart, using the polarization and depolarization of the heart during the cardiac cycle. This was at AHA.18, AHA 2018 - the American Heart Association annual meeting

The startup company Genetesis introduced a new cardiac imaging modality it calls magnetocardiography. The scanner creates images from the biomagnetic activity of the heart, using the polarization and depolarization of the heart during the cardiac cycle.

Feature | AHA | January 14, 2019 | Dave Fornell, Editor
Here are a few of the takeaways from the clinical studies presented and new technology shown on the exhibit floor at...
Aurobindo Pharma Adds to Nationwide Valsartan Blood Pressure Medication Recall
News | Pharmaceuticals | January 10, 2019
January 10, 2019 — Aurobindo Pharma USA Inc. is conducting a voluntary recall of 80 lots of Amlodipine Valsartan...
The 2018 Most Popular Cardiology Topics - FDA approval of Andexxa, the first antidote indicated for patients treated with rivaroxaban (Xarelto) and apixaban (Eliquis), and new pacemaker technologies.

The top two articles on DAIC from 2018 included the FDA approval of Andexxa, the first antidote indicated for patients treated with the anticoagulants rivaroxaban (Xarelto) and apixaban (Eliquis), and an article on new pacemaker technologies. 

Feature | January 04, 2019 | Dave Fornell, Editor
January 4, 2018 — Here is the top cardiology content on the Diagnostic and Interventional Cardiology (DAIC) website...
Breast Cancer Patients Have Less Heart Damage With Heart Drug and Trastuzumab
News | Cardio-oncology | January 03, 2019
January 3, 2019 — Breast cancer patients who take a heart drug at the same time as trastuzumab have less heart damage,...
FDA Approves Portola Pharmaceuticals' Prior Approval Supplement for Andexxa Generation 2 Manufacturing Process
News | Antiplatelet and Anticoagulation Therapies | January 02, 2019
January 2, 2019 — The U.S. Food and Drug Administration (FDA) has approved Portola Pharmaceuticals’ Prior Approval...
Daily Aspirin Use May Do More Harm Than Good for Healthy People
News | Antiplatelet and Anticoagulation Therapies | December 17, 2018
December 17, 2018 — Among otherwise healthy people, a daily dose of aspirin does not save lives and causes additional...
Mylan Expands Nationwide Recall of Valsartan Blood Pressure Medication
News | Pharmaceuticals | December 11, 2018
December 11, 2018 — Mylan Pharmaceuticals is expanding its consumer-level voluntary nationwide recall to include all...
Xarelto Reduces Blood Clot Events in High-Risk Cancer Patients
News | Cardio-oncology | December 07, 2018
December 7, 2018 — New data from the Phase 3 CASSINI study showed a 60 percent reduction of venous thromboembolism (VTE...
Livongo Launches Applied Health Signals Product Category
News | Cardiac Diagnostics | November 30, 2018
November 30, 2018 — Healthcare technology company Livongo recently announced the launch of its Applied Health Signals...
A urine test can show patient compliance with taking their hypertension, high blood pressure, medications.
News | November 19, 2018
November 16, 2018 — A research team led by scientists and doctors in Leicester and the Netherlands has shown that a...